# EDGAR Filing Document

**Accession Number:** 0001648257
**File Stem:** 0001648257-23-000010
**Filing Date:** 2023-1
**Character Count:** 6317
**Document Hash:** a1c39adb27dc497c3bf7864f5dfce6c4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001648257-23-000010.hdr.sgml**: 20230131

**ACCESSION NUMBER**: 0001648257-23-000010

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20230131

**FILED AS OF DATE**: 20230131

**DATE AS OF CHANGE**: 20230131

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HUTCHMED (China) Ltd
- **CENTRAL INDEX KEY:** 0001648257
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** E9

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37710
- **FILM NUMBER:** 23570136

**BUSINESS ADDRESS:**
- **STREET 1:** 48TH FLOOR, CHEUNG KONG CENTER
- **STREET 2:** 2 QUEEN'S ROAD CENTRAL
- **CITY:** HONG KONG
- **STATE:** K3
- **ZIP:** 00000
- **BUSINESS PHONE:** 852-2121-3888

**MAIL ADDRESS:**
- **STREET 1:** 48TH FLOOR, CHEUNG KONG CENTER
- **STREET 2:** 2 QUEEN'S ROAD CENTRAL
- **CITY:** HONG KONG
- **STATE:** K3
- **ZIP:** 00000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Hutchison China MediTech Ltd
- **DATE OF NAME CHANGE:** 20150716

------

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM 6-K**

------

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13A-16 OR 15D-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the Month of January 2023**

**Commission File Number: 001-37710**

------

**HUTCHMED (CHINA) LIMITED**

(Translation of registrant's name into English)

------

**48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong**

(Address of principal executive offices)

------

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ⌧ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ◻

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ◻

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

------

**HUTCHMED (CHINA) LIMITED**

**Form 6-K**

<u>EXHIBIT INDEX</u>

---

| | | |
|:---|:---|:---|
| **Exhibit No.** |  | **Description** |
| Exhibit 99.1 |  | Announcement relating to notice of announcement of 2022 final results |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| HUTCHMED (CHINA) LIMITED | HUTCHMED (CHINA) LIMITED |
| By: | /s/ Johnny Cheng |
| Name: | Johnny Cheng |
| Title: | Chief Financial Officer |

---

Date: January 31, 2023

------

## Exhibit 99.1

**Exhibit 99.1**

![GRAPHIC](hcm-20230131xex99d1001.jpg)

**HUTCHMED to Announce 2022 Final Results**

<br>**Hong Kong, Shanghai & Florham Park, NJ — Tuesday, January 31, 2023:** HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2022 on Tuesday, February 28, 2023 at 3:30 am Eastern Standard Time (EST) / 8:30 am Greenwich Mean Time (GMT) / 4:30 pm Hong Kong Time (HKT).

Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management.

The conference call and audio webcast will take place at 8:00 am EST / 1:00 pm GMT / 9:00 pm HKT on Tuesday, February 28, 2023 and will be webcast live via the company website at www.hutch-med.com/event/. The presentation will be available for downloading before the conference call begins. Details of the conference call dial-in will be provided in the financial results announcement and on the company website. A replay will also be available on the website shortly after the event.

**About HUTCHMED** 

HUTCHMED (Nasdaq/AІM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. Іt is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Іt has more than 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception HUTCHMED has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

**CONTACTS**

---

| | |
|:---|:---|
| **Investor Enquiries** |  |
| &nbsp;&nbsp;&nbsp;Mark Lee, Senior Vice President | +852 2121 8200 |
| &nbsp;&nbsp;&nbsp;Annie Cheng, Vice President | +1 (973) 567 3786 |
| **Media Enquiries** |  |
| &nbsp;&nbsp;&nbsp;**Americas –** Brad Miles, Solebury Trout  | +1 (917) 570 7340 (Mobile) / <u>bmiles@troutgroup.com</u> |
| &nbsp;&nbsp;&nbsp;**Europe** – Ben Atwell / Alex Shaw, <br>FTI Consulting | +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) <br><u>HUTCHMED@fticonsulting.com</u> |
| &nbsp;&nbsp;&nbsp;**Asia** – Zhou Yi, <br>Brunswick | +852 9783 6894 (Mobile) / <u>HUTCHMED@brunswickgroup.com</u><br>|
| **Nominated Advisor** |  |
| &nbsp;&nbsp;&nbsp;Atholl Tweedie / Freddy Crossley, <br>Panmure Gordon (UK) Limited | +44 (20) 7886 2500 |

---

------